A Replication-Defective Myxoma Virus Inducing Pro-Inflammatory Responses as Monotherapy and an Adjuvant to Chemo- and DC Immuno-Therapy for Ovarian Cancer.

Abstract read

In one paragraph

Article in Viruses, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors.

Martin J CannonDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA.ORCID 0000-0003-2656-187X

Jia LiuDepartment of Microbiology and Immunology, University of Arkansas for Medical Sciences (UAMS), Little Rock, AR 72205, USA.ORCID 0000-0001-8424-7972

Funding

Study of the Cell-specific Inflammasome Responses During Defense Against Gram-negative BacteriaP20GM103625 · NIGMS · UNIV OF ARKANSAS FOR MED SCIS · PI SMELTZER, MARK S · 2012 to 2021

$21.5M

Studies in Poxvirus Evasion of SAMD9 PathwayR01AI139106 · NIAID · UNIV OF ARKANSAS FOR MED SCIS · PI LIU, JIA · 2019 to 2023

$1.9M

APOBEC3-driven host mechanism promotes poxvirus diversification to overcome host immune restrictionR21AI191013 · NIAID · UNIV OF ARKANSAS FOR MED SCIS · PI Jia Liu · 2025 to 2026

$391k

NIAID NIH HHS R01 AI139106NIAID NIH HHS R21 AI191013NIGMS NIH HHS P20 GM103625NIH HHS R01AI139106

6 · The paper itself

Abstract

Myxoma virus (MYXV), a rabbit-specific poxvirus and non-pathogenic in humans and mice, is an excellent candidate oncolytic virus for cancer therapy. MYXV also has immunotherapeutic benefits. In ovarian cancer (OC), immunosuppressive tumor-associated macrophages (TAMs) are key to inhibiting antitumor immunity while hindering therapeutic benefit by chemotherapy and dendritic cell (DC) vaccine. Because MYXV favors binding/entry of macrophages/monocytes, we examined the therapeutic potential of MYXV against TAMs. We found previously that a replication-defective MYXV with targeted deletion of an essential gene,

Indexed as

Dendritic CellsImmunotherapyMyxoma virusOncolytic VirotherapyOncolytic VirusesOvarian NeoplasmsAdjuvants, ImmunologicAnimalsCell Line, TumorFemaleHumansMiceVirus ReplicationAdjuvants, Immunologichost range factorimmunoregulatoryimmunotherapy platformmyxoma virusoncolytic virusproinflammatorytype 1 interferontype 1 interferon stimulated genes

Identifiers

PMID40872773

DOI10.3390/v17081058

PMCPMC12390723

What OpenQuestion holds

Textmetadata

LicenceCC BY

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.